Pexmetinib NEW
| Price | $93 | $135 | $272 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Pexmetinib | CAS No.: 945614-12-0 |
| Purity: 99.65% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Pexmetinib |
| Description | Pexmetinib (ARRY-614) is an orally bioavailable dual p38 MAPK/Tie-2 inhibitor studied in acute myeloid leukemia and inhibits osteoclastogenesis and breast cancer-induced osteolysis via the P38/STAT3 signaling pathway. |
| In vitro | METHODS: HEK-Tie2 cells were treated with Pexmetinib (ARRY-614) (0.05, 0.15, 0.5, 1.3, 4.1, 12, 37, 333, 1000 nM), and Western blot was used to evaluate the efficacy of direct or proximal inhibition of p-Tie-2 and p-p38 MAPK. RESULTS The IC50 values ??of Pexmetinib for inhibition of p-Tie-2 and p-p38 in cells were 16 and 1 nM, respectively. [1] METHODS: MDA-MB-231 cells were treated with pexmetinib (ARRY-614) (4 μM), and the levels of the indicated proteins were measured by Western blotting at 0 h, 6 h, 12 h, and 24 h after treatment. RESULTS Pexmetinib treatment inhibited the phosphorylation of p38 and STAT3 in MDA-MB-231 cells. [2] |
| In vivo | METHODS: Pexmetinib (ARRY-614) Pexmetinib (10 mg/kg, intraperitoneal injection, once every 3 days, 1 month) was used to treat tumor xenograft model mice injected with MDA-MB-231 cells into the tibia to test the effect of Pexmetinib on breast cancer cells Caused by osteolytic bone damage. RESULTS Tissue volume, tissue length, and tissue weight were reduced in xenograft mice treated with Pexmetinib; p-STAT3 was significantly reduced in the Pexmetinib-treated group. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 93 mg/mL (167.08 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (5.93 mM), Sonication is recommended. Ethanol : 93 mg/mL (167.08 mM), Sonication is recommended. |
| Keywords | Tie-2 | Tie2 | Pexmetinib | p38MAPK | p38 MAPK | Inhibitor | inhibit | Autophagy | ARRY614 | ARRY 614 |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | D-Psicose | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2019-12-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY